Clinical efficacy and safety of indomethacin-gyneFix IUD combined with a levonorgestrel-releasing intrauterine system in patients with adenomyosis and different uterine cavity depths.
Peipei Li, Tuo He, Jiajia Pan et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy and safety of the Indomethacin-GyneFix IUD combined with a levonorgestrel-releasing intrauterine system (LNG-IUS) in 270 patients with adenomyosis. The study found that the displacement/expulsion rate at 6 months was significantly lower in the GyneFix IUD + LNG-IUS group (2.22%) compared to the ring IUD + LNG-IUS (10.00%) and LNG-IUS alone (18.89%), indicating improved device stability.
Key findings
- Displacement/expulsion rate was 2.22% for GyneFix IUD + LNG-IUS vs 10.00% for ring IUD + LNG-IUS and 18.89% for LNG-IUS alone.
- All groups showed significant improvement in dysmenorrhea and menstrual blood loss compared to baseline.
- Patient willingness to choose the same treatment again was 95.12% in the GyneFix IUD + LNG-IUS group.
- The stability advantage of GyneFix IUD + LNG-IUS was more pronounced in patients with uterine cavity depth >9 cm.
Why it matters
The findings suggest that combining the GyneFix IUD with LNG-IUS may offer a more stable treatment option for patients with adenomyosis, particularly those with deeper uterine cavities, potentially improving patient outcomes and satisfaction.